BCL2 and hematologic disorder: According to the above studies, researchers have gradually realized that BCL-2-specific inhibitors may become new antitumor drugs for hematological malignancies, and the first highly selective and effective BCL-2 inhibitor, ABT-199 (Venetoclax), was studied in this context.